SSFA2 Antibody

What is SSFA2 and what are its known functions?

SSFA2 (Sperm Specific Antigen 2) is a protein also known by several aliases including KRAP (Ki-ras-induced actin-interacting protein), ITPRID2 (ITPR-interacting domain-containing protein 2), CS-1 (Cleavage signal-1 protein), and SPAG13 (sperm associated antigen 13). Gene ontology annotations indicate that SSFA2 has actin-binding capability . Recent research has demonstrated that SSFA2 plays a critical role in acrosome formation during spermatogenesis . The protein can tether IP3 receptors (IP3Rs) to actin alongside sites and license IP3Rs to evoke Ca2+ puffs, suggesting a role in calcium signaling . Additionally, SSFA2 has been found to interact with GSTM3 and Actin, which likely contributes to maintaining proper sperm head morphology .

What are the common applications for SSFA2 antibodies in research?

SSFA2 antibodies are versatile research tools with multiple validated applications:

These applications enable researchers to study SSFA2 expression patterns, subcellular localization, and protein interactions across different experimental systems .

What species reactivity should researchers consider when selecting an SSFA2 antibody?

When selecting an SSFA2 antibody, species reactivity is a critical consideration that depends on your experimental model:

For cross-species applications, verify the sequence homology in your region of interest. For example, some antibodies targeting specific amino acid regions (e.g., AA 276-510 or AA 587-802) might have different cross-reactivity profiles than those targeting other epitopes .

How should researchers optimize immunofluorescence protocols when using SSFA2 antibodies for sperm studies?

Based on published methodologies, optimizing immunofluorescence for SSFA2 in sperm studies requires:

• Sample preparation:

  • Fix samples appropriately (paraformaldehyde is commonly used)

  • Permeabilize with 0.1% Triton X-100 to access intracellular antigens

• Antibody incubation:

  • Use SSFA2 antibody at 1:200 dilution (14,157-1-AP, Proteintech has been validated)

  • Incubate overnight at 4°C for optimal binding

• Co-staining markers:

  • PNA (Peanut agglutinin) conjugated with AlexaFluor 488 (1:100) as an acrosome marker

  • DAPI for nuclear counterstaining

• Secondary antibody selection:

  • Alexa Fluor 488 (1:1000; A21206) or Alexa Fluor 594 (1:1000; A11005) labeled secondary antibodies

  • Incubate for 1 hour at room temperature

• Controls:

  • Include negative controls (secondary antibody only)

  • Use positive controls with known SSFA2 expression

This protocol has successfully demonstrated SSFA2 localization in the acrosome of human sperm, which is critical for understanding its role in spermatogenesis and fertility .

What are the recommended approaches for validating a new SSFA2 antibody in Western blot applications?

Comprehensive validation of SSFA2 antibodies for Western blot should include:

• Protein sample preparation:

  • Test multiple tissue/cell sources (testicular tissue shows high expression)

  • Include positive controls (HEK293T cells with overexpressed SSFA2)

  • Prepare negative controls (knockdown or tissues with minimal expression)

• Loading controls and molecular weight verification:

  • Use α-Tubulin (1:5000) or GAPDH (1:5000) as loading controls

  • Verify band at expected molecular weight (~140 kDa for human SSFA2)

  • Test wild-type and mutant SSFA2 expression to confirm specificity

• Antibody optimization:

  • Test dilution range (1:500-1:3000 is recommended)

  • Optimize blocking conditions (typically 5% non-fat milk or BSA)

  • Compare different antibodies targeting different epitopes if available

• Validation approaches:

  • Demonstrate reduced signal in samples with known SSFA2 variants (e.g., c.3671G>A variant)

  • Confirm with recombinant protein

  • Use Flag-tagged or Myc-tagged SSFA2 as additional verification

This multi-faceted approach ensures both specificity and sensitivity in Western blot applications for SSFA2 detection.

What are the critical considerations for coimmunoprecipitation experiments using SSFA2 antibodies?

Successful coimmunoprecipitation (Co-IP) experiments with SSFA2 antibodies require attention to:

• Lysis conditions:

  • Use RIPA buffer supplemented with protease inhibitor cocktail

  • Optimize protein extraction specifically for protein-protein interactions

• Antibody selection:

  • Use anti-SSFA2 (14157-1-AP, Proteintech) for IP of endogenous SSFA2

  • For tagged proteins, consider anti-Flag (TA-05) or anti-Myc (TA-01) antibodies

• IP methodology:

  • Incubate extracted total proteins with target antibodies overnight at 4°C

  • Use Protein A/G magnetic beads, incubating for 1 hour at room temperature

  • Wash three times with 1× PBS to reduce non-specific binding

  • Elute with standard 1× SDS sample buffer (heat for 10 min at 95°C)

• Detection of interacting partners:

  • Based on published research, consider probing for:

    • F-Actin (ab205, Abcam)

    • GSTM3 (67,634-1-Ig, Proteintech)

    • Other potential interactors identified by LC-MS/MS analysis

• Controls:

  • Include IgG control

  • Perform reciprocal Co-IP (pull down with interactor antibody)

  • Verify interactions with multiple antibodies if possible

This approach has successfully identified GSTM3 and Actin as interaction partners of SSFA2, providing insights into its molecular function in acrosome formation .

How can researchers effectively investigate the role of SSFA2 in globozoospermia using antibody-based approaches?

Investigating SSFA2's role in globozoospermia requires a multi-dimensional approach:

• Immunofluorescence analysis of patient samples:

  • Compare SSFA2 localization in sperm from globozoospermia patients and controls

  • Co-stain with acrosome markers (PNA) to assess acrosome formation

  • Quantify SSFA2 signal intensity and distribution across different patient groups

• Protein expression analysis in variant carriers:

  • Use Western blot to assess SSFA2 protein levels in patients with identified variants

  • Correlate protein expression with specific variants (e.g., c.3671G>A)

• Functional validation in cellular models:

  • Create expression plasmids for wild-type and mutant SSFA2 (using Mut Express II Fast Mutagenesis Kit)

  • Transfect into appropriate cell lines (e.g., HEK293T)

  • Compare protein expression, localization and interaction capabilities

• Spermatogenic cell isolation and analysis:

  • Utilize STA-PUT velocity sedimentation to isolate specific spermatogenic cell populations

  • Apply stage-specific analysis of SSFA2 expression and localization during spermatogenesis

• Calcium signaling assessment:

  • Given SSFA2's role in tethering IP3 receptors, investigate calcium signaling in patient sperm

  • Correlate SSFA2 antibody staining with PLCζ expression (calcium release factor)

This comprehensive approach can link specific SSFA2 variants to globozoospermia and potential treatment approaches, as demonstrated in a case where artificial oocyte activation (AOA) after ICSI overcame fertility issues in a patient with an SSFA2 variant .

What strategies can resolve inconsistent results when using different SSFA2 antibodies in experimental protocols?

When facing inconsistent results with different SSFA2 antibodies, implement these systematic troubleshooting approaches:

• Epitope mapping comparison:

  • Create a table of antibodies with their target epitopes (e.g., AA 276-510, AA 587-802, AA 1-267)

  • Cross-reference with known domains and functional regions of SSFA2

  • Check for potential post-translational modifications or protein isoforms that might affect epitope accessibility

• Validation across multiple techniques:

  • Compare antibody performance across different applications (WB, IHC, IF)

  • Use orthogonal methods to confirm expression (e.g., mRNA analysis)

  • Consider epitope tags if working with recombinant systems

• Optimization of experimental conditions:

  • Systematically vary antibody concentrations, incubation times, temperatures

  • Test different antigen retrieval methods for IHC/IF applications

  • Evaluate buffer compositions that might affect epitope recognition

• Positive and negative controls:

  • Include samples with confirmed high and low/no expression

  • Use SSFA2 knockout/knockdown models if available

  • Test with recombinant SSFA2 protein

• Cross-validation with tagged constructs:

  • Generate Flag-tagged or Myc-tagged SSFA2 constructs

  • Compare antibody detection with tag-specific antibodies

  • Use this approach to calibrate relative sensitivity of different SSFA2 antibodies

This systematic approach can help identify which antibodies are most reliable for specific applications and experimental conditions.

How can researchers use SSFA2 antibodies to investigate potential relationships between SSFA2 and antiphospholipid antibodies in disease contexts?

The intersection of SSFA2 and antiphospholipid antibodies (aPL) presents an intriguing research direction that could be explored using these methodological approaches:

• Colocalization studies in relevant tissues:

  • Use SSFA2 antibodies in immunofluorescence studies of tissues from patients with antiphospholipid syndrome (APS) or sickle cell disease (SCD)

  • Assess whether SSFA2 and aPL targets (e.g., β2 glycoprotein I) colocalize in affected tissues

  • Quantify signal overlap using confocal microscopy and colocalization analysis

• Protein-protein interaction analysis:

  • Perform coimmunoprecipitation experiments with SSFA2 antibodies in samples from patients with elevated aPL

  • Investigate whether SSFA2 interacts with components of the aPL pathway

  • Use LC-MS/MS to identify potential novel interaction partners

• Cross-sectional and longitudinal studies:

  • Measure SSFA2 expression levels in patient cohorts with varying aPL titers

  • Track changes in SSFA2 expression over time, particularly during disease flares

  • Correlate findings with clinical parameters and aPL subtypes (IgG aCL, IgM aCL, LA)

• Functional assays:

  • Investigate calcium signaling pathways in cells expressing SSFA2 when exposed to aPL

  • Assess whether SSFA2's interaction with IP3 receptors is affected by aPL

  • Determine if aPL alter SSFA2's actin-binding properties

• Statistical approaches:

  • Apply statistical methods similar to those used in meta-analyses of aPL in sickle cell disease

  • Calculate pooled prevalence (PP) of various parameters

  • Assess heterogeneity using I² statistics and perform sensitivity analyses

This research direction could provide valuable insights into potential mechanisms connecting reproductive biology, calcium signaling, and autoimmune phenomena in conditions like APS or SCD where aPL have been implicated .

What criteria should be applied when interpreting SSFA2 immunostaining patterns in different cell types?

Accurate interpretation of SSFA2 immunostaining requires careful consideration of:

• Expected subcellular localization:

  • In sperm: Primarily acrosomal localization

  • In somatic cells: May show cytoplasmic and membrane-associated patterns

  • Potential nuclear localization in certain cell types

• Pattern analysis guidelines:

  Cell Type	Expected Pattern	Potential Artifacts	Validation Approach
  Sperm	Acrosome-specific, crescent-shaped	Background in midpiece	Co-stain with PNA
  Testicular cells	Stage-dependent during spermatogenesis	Autofluorescence	Use autofluorescence controls
  Somatic cells	Cytoplasmic with potential membrane association	Nuclear retention	Compare multiple fixation methods

• Controls for interpretation:

  • Include positive controls with known SSFA2 expression

  • Use samples with confirmed SSFA2 variants/mutations

  • Compare patterns with multiple antibodies targeting different epitopes

• Quantification approaches:

  • Measure signal intensity relative to background

  • Assess percentage of cells showing specific patterns

  • Quantify colocalization with relevant markers (e.g., acrosomal markers)

• Consideration of experimental variables:

  • Fixation methods may affect epitope accessibility

  • Antibody concentration affects signal-to-noise ratio

  • Sample preparation (fresh vs. frozen vs. paraffin) influences staining quality

Careful application of these criteria has enabled researchers to successfully identify the acrosomal localization of SSFA2 in human sperm and correlate expression patterns with functional outcomes in fertility studies .

How should researchers interpret discrepancies between SSFA2 protein levels detected by antibodies and mRNA expression data?

When facing discrepancies between SSFA2 protein and mRNA levels, consider these analytical approaches:

• Post-transcriptional regulation assessment:

  • Investigate microRNA regulation of SSFA2

  • Examine RNA-binding proteins that might affect SSFA2 mRNA stability

  • Consider alternative splicing that might affect antibody recognition sites

• Protein stability and turnover analysis:

  • Assess post-translational modifications affecting SSFA2 stability

  • Investigate proteasomal degradation pathways

  • Examine potential protein-protein interactions that might stabilize or destabilize SSFA2

• Technical considerations matrix:

  Issue	Protein Detection	mRNA Detection	Resolution Approach
  Sensitivity	Antibody affinity limitations	RT-qPCR efficiency	Calibration curves with standards
  Specificity	Cross-reactivity	Primer specificity	Multiple detection methods
  Sample preparation	Protein degradation	RNA quality	Standardized protocols with QC steps
  Isoform detection	Epitope availability	Primer location	Isoform-specific detection methods

• Biological verification approaches:

  • Test protein expression in systems with known SSFA2 variants

  • Create reporter systems to track transcription and translation separately

  • Perform pulse-chase experiments to assess protein turnover rates

• Data integration strategies:

  • Normalize data across platforms for comparison

  • Apply statistical methods to quantify discrepancies

  • Consider temporal factors (mRNA changes may precede protein changes)

This systematic approach can help distinguish technical artifacts from biologically meaningful differences between transcription and translation/post-translational regulation of SSFA2.

What are the best practices for troubleshooting non-specific binding when using SSFA2 antibodies in complex tissue samples?

When encountering non-specific binding in complex tissues, implement these systematic troubleshooting strategies:

• Blocking optimization:

  • Test different blocking agents (BSA, normal serum, commercial blockers)

  • Optimize blocking time and temperature

  • Consider specialized blocking for tissues with high endogenous biotin or peroxidase activity

• Antibody dilution and incubation optimization:

  • Create a dilution series to identify optimal concentration

  • Test different diluents (PBS with varying detergent concentrations)

  • Compare overnight incubation at 4°C vs. shorter times at room temperature

• Washing protocol refinement:

  • Increase washing steps and duration

  • Test different wash buffers (PBS, TBS, with varying detergent concentrations)

  • Include salt washes to reduce ionic interactions

• Cross-adsorption techniques:

  • Pre-adsorb antibody with tissue homogenates from negative control samples

  • Use recombinant SSFA2 for specific adsorption tests

  • Consider commercial cross-adsorbed secondary antibodies

• Detection system optimization:

  Issue	Chromogenic Detection	Fluorescence Detection	Resolution Approach
  High background	Reduce substrate incubation	Use higher dilutions	Titrate reagents systematically
  Edge effects	Humidity chamber	Hydrophobic barriers	Optimize incubation conditions
  Tissue autofluorescence	N/A	Spectral unmixing	Include unstained controls
  Endogenous peroxidase	H₂O₂ quenching	N/A	Optimize quenching conditions

• Control experiments:

  • Include antibody-omission controls

  • Use isotype controls

  • Test pre-immune serum if available

  • Include absorption controls with immunizing peptide

These approaches have been successfully applied in studies of SSFA2 in reproductive tissues, which are known for challenging background issues due to high lipid content and complex cellular composition .

How can SSFA2 antibodies be applied to study the relationship between calcium signaling and acrosome formation in male fertility research?

SSFA2 antibodies offer unique opportunities to investigate the calcium-acrosome-fertility axis through:

• Calcium imaging in correlation with SSFA2 localization:

  • Use SSFA2 antibodies in combination with calcium indicators

  • Track calcium dynamics in sperm with different SSFA2 expression patterns

  • Correlate SSFA2 localization with calcium oscillation patterns during capacitation and acrosome reaction

• IP3R-SSFA2-actin interaction studies:

  • Apply proximity ligation assay using SSFA2 antibodies and IP3R antibodies

  • Quantify SSFA2-IP3R interactions in normal vs. globozoospermia samples

  • Investigate how SSFA2 variants affect IP3R tethering to actin

• Therapeutic strategy evaluation:

  • Use SSFA2 antibodies to assess protein levels/localization before and after calcium ionophore treatment

  • Correlate SSFA2 patterns with oocyte activation outcomes in ICSI/AOA procedures

  • Develop predictive models for ICSI success based on SSFA2 immunostaining patterns

• Developmental tracking of SSFA2-calcium axis:

  • Apply SSFA2 antibodies to study expression throughout spermatogenesis

  • Correlate with calcium signaling proteins at different developmental stages

  • Investigate potential regulatory mechanisms during acrosome biogenesis

• Comparative analysis across fertility conditions:

  Condition	SSFA2 Analysis Approach	Calcium Assessment	Correlation Method
  Globozoospermia	Quantitative IF with SSFA2 antibodies	Calcium ionophore response	Statistical correlation
  Acrosome reaction defects	Time-course of SSFA2 localization	Calcium oscillation patterns	Time-series analysis
  ICSI failure cases	SSFA2 variant identification	PLCζ co-staining	Predictive modeling

This research direction builds on the demonstrated connection between SSFA2 variants, globozoospermia, calcium signaling defects, and successful treatment with calcium ionophore during artificial oocyte activation .

What methodological approaches can integrate SSFA2 antibody-based detection with advanced genomic analysis in reproductive medicine?

Integration of SSFA2 antibody-based detection with genomic analysis can be achieved through:

• Genotype-phenotype correlation pipeline:

  • Sequence SSFA2 gene in fertility patients (whole-exome sequencing)

  • Apply SSFA2 antibodies to assess protein expression/localization in the same cohort

  • Correlate specific variants (e.g., c.3671G>A) with protein parameters

  • Develop statistical models linking genotype to protein phenotype

• Multimodal analysis framework:

  Genomic Approach	Antibody Application	Integration Method
  WES/targeted sequencing	Quantitative immunofluorescence	Machine learning algorithms
  RNA-seq for expression	Western blot for protein levels	Correlation analysis
  ChIP-seq for regulation	Co-IP for protein interactions	Network analysis
  CRISPR-edited models	Immunolocalization	Direct causality testing

• Single-cell multi-omics approaches:

  • Apply SSFA2 antibodies in single-cell immunofluorescence

  • Combine with single-cell RNA-seq or DNA-seq

  • Develop computational methods to integrate protein localization with transcriptomic/genomic data

• Translational research pipeline:

  • Screen for SSFA2 variants in infertility patients

  • Apply SSFA2 antibodies to assess protein impact

  • Develop predictive algorithms for treatment selection

  • Follow treatment outcomes (e.g., success of ICSI vs. AOA-ICSI)

• Database development:

  • Catalog SSFA2 variants and their protein-level consequences

  • Document antibody-based detection results across variants

  • Create searchable resources for clinicians and researchers

This integrated approach has already demonstrated clinical value, as evidenced by the case where identification of an SSFA2 variant led to successful treatment modification (AOA-ICSI instead of regular ICSI), resulting in a live birth for a couple affected by male infertility .

How can liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) be integrated with SSFA2 antibody-based approaches to identify novel protein interactions?

Integration of LC-MS/MS with SSFA2 antibody techniques enables comprehensive protein interaction discovery through this workflow:

• Sample preparation optimization:

  • Extract proteins from relevant tissues (testis or sperm samples)

  • Use SSFA2 antibodies for immunoprecipitation under native conditions

  • Prepare parallel samples with different detergent conditions to capture diverse interaction types

• IP-MS workflow:

  • Perform immunoprecipitation with SSFA2 antibodies

  • Process samples according to standardized protocols (as done by Hangzhou Jingjie Biotechnology)

  • Include appropriate controls (IgG control, lysate control)

• Data analysis pipeline:

  Analysis Step	Approach	Output
  Protein identification	Database searching (e.g., UniProt)	List of potential interactors
  Filtering	Comparison to IgG control	Removal of non-specific binders
  Network analysis	Protein interaction databases	Functional clusters
  Gene ontology	Enrichment analysis	Biological processes involved

• Validation strategies:

  • Confirm top candidates (e.g., GSTM3, Actin) by reciprocal Co-IP

  • Perform colocalization studies using antibodies against identified partners

  • Use proximity ligation assay to verify interactions in situ

• Functional characterization:

  • Investigate biological significance of validated interactions

  • Study effects of SSFA2 variants on interaction profiles

  • Correlate interaction disruptions with functional outcomes